Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 8/20 | 0.36 |
| ▸ | CDK2 | P24941 | 8/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559144 | 1.00 | CCNE1 (0.36) | CCNE1CDK2MAPK1ROCK2ROCK1 | |
| SCHEMBL3136001 | 0.89 | MAPK1 (0.40) | CCNE1CDK2MAPK1ROCK2GSK3B | |
| SCHEMBL3136006 | 0.89 | MAPK1 (0.40) | CCNE1CDK2MAPK1ROCK2GSK3B | |
| SCHEMBL3565829 | 0.79 | CCR2 (0.34) | CCNE1CDK2ROCK1GSK3B | |
| SCHEMBL3130755 | 0.74 | HTR1A (0.36) | CCNE1CDK2GSK3B | |
| SCHEMBL3130764 | 0.74 | HTR1A (0.36) | CCNE1CDK2GSK3B | |
| SCHEMBL3130751 | 0.74 | HTR1A (0.36) | CCNE1CDK2GSK3B | |
| SCHEMBL3561897 | 0.72 | CCR2 (0.40) | CDK2P2RX7 | |
| SCHEMBL3260122 | 0.71 | CETP (0.39) | ROCK1P2RX7 | |
| SCHEMBL3121250 | 0.70 | PKM (0.43) | CCNE1CDK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | claimed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | CCNE1 420/4885CDK2 58/4885MAPK1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.